Reduced expression of PDCD5 is associated with high-grade astrocytic gliomas

被引:53
|
作者
Li, Haiyan [1 ]
Wang, Qun [1 ]
Gao, Fei [1 ]
Zhu, Faliang [1 ]
Wang, Xiaoyan [1 ]
Zhou, Chengjun [2 ]
Liu, Chunmei [1 ]
Chen, Yingyu [3 ]
Ma, Chunhong [1 ]
Sun, Wensheng [1 ]
Zhang, Lining [1 ]
机构
[1] Shandong Univ, Sch Med, Inst Immunol, Jinan 250012, Shandong, Peoples R China
[2] Shandong Univ, Hosp 2, Dept Pathol, Jinan 250021, Shandong, Peoples R China
[3] Peking Univ, Ctr Human Dis Genom, Beijing 100083, Peoples R China
关键词
programmed cell death 5; glioma; gene expression;
D O I
10.3892/or_00000044
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Programmed cell death 5 (PDCD5) is a novel apoptosis-promoting protein. Recently, a decreased expression of PDCD5 has been found in several types of human tumors. However, the expression level of PDCD5 in human gliomas has not been investigated. In the present study, we examined the expression of PDCD5 in 88 human glioma samples at both mRNA and protein levels by RT-PCR, Western blotting and immunohistochemistry. We found that 53.3% (16/30) of the glioma samples had a reduced expression of PDCD5 mRNA and 70.5% (62/88) had a reduced expression of the PDCD5 protein as compared to normal brain tissue. Furthermore, we studied the correlation of the expression level of PDCD5 with the clinicopathological grade and survival of patients with astrocytomas. Although longitudinal studies of a cohort of patients with astrocytoma revealed that PDCD5 expression was not able to predict clinical outcome (p > 0.05), a decreased expression of PDCD5 correlated significantly with high-grade astrocytomas (p < 0.001). In conclusion, our data suggest that reduced PDCD5 expression may contribute to the pathogenesis of human gliomas.
引用
收藏
页码:573 / 579
页数:7
相关论文
共 50 条
  • [1] Expression of PROX1 Is a Common Feature of High-Grade Malignant Astrocytic Gliomas
    Elsir, Tarnador
    Eriksson, Anna
    Orrego, Abiel
    Lindstrom, Mikael S.
    Nister, Momca
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2010, 69 (02): : 129 - 138
  • [2] High-Grade Gliomas
    Brett J. Theeler
    Morris D. Groves
    Current Treatment Options in Neurology, 2011, 13 : 386 - 399
  • [3] High-Grade Gliomas
    Theeler, Brett J.
    Groves, Morris D.
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2011, 13 (04) : 386 - 399
  • [4] High-grade gliomas
    Haase, Jens
    SURGICAL NEUROLOGY, 2008, 70 (06): : 598 - 598
  • [5] Differential expression of microRNAs targeting genes associated with the development of high-grade gliomas
    Oleg I. Kit
    Anton A. Pushkin
    Ilya A. Alliluyev
    Nataliya N. Timoshkina
    Dmitry Y. Gvaldin
    Eduard E. Rostorguev
    Nataliya S. Kuznetsova
    Egyptian Journal of Medical Human Genetics, 23
  • [6] Identification of the immune gene expression signature associated with recurrence of high-grade gliomas
    Adria-Jaume Roura
    Bartlomiej Gielniewski
    Paulina Pilanc
    Paulina Szadkowska
    Marta Maleszewska
    Sylwia K. Krol
    Ryszard Czepko
    Wojciech Kaspera
    Bartosz Wojtas
    Bozena Kaminska
    Journal of Molecular Medicine, 2021, 99 : 241 - 255
  • [7] Differential expression of microRNAs targeting genes associated with the development of high-grade gliomas
    Kit, Oleg I.
    Pushkin, Anton A.
    Alliluyev, Ilya A.
    Timoshkina, Nataliya N.
    Gvaldin, Dmitry Y.
    Rostorguev, Eduard E.
    Kuznetsova, Nataliya S.
    EGYPTIAN JOURNAL OF MEDICAL HUMAN GENETICS, 2022, 23 (01)
  • [8] Identification of the immune gene expression signature associated with recurrence of high-grade gliomas
    Roura, Adria-Jaume
    Gielniewski, Bartlomiej
    Pilanc, Paulina
    Szadkowska, Paulina
    Maleszewska, Marta
    Krol, Sylwia K.
    Czepko, Ryszard
    Kaspera, Wojciech
    Wojtas, Bartosz
    Kaminska, Bozena
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2021, 99 (02): : 241 - 255
  • [9] Chemotherapy for high-grade gliomas
    Galanis, E
    Buckner, J
    BRITISH JOURNAL OF CANCER, 2000, 82 (08) : 1371 - 1380
  • [10] High-Grade Gliomas Preface
    Haas-Kogan, Daphne
    SEMINARS IN RADIATION ONCOLOGY, 2014, 24 (04) : 233 - 234